# Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

> **NCT06370754** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 117 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** JS001
- **DRUG:** JS004
- **DRUG:** JS007
- **DRUG:** JS015
- **DRUG:** Irinotecan Liposome Injection
- **DRUG:** 5-Fluorouracil (5-FU)
- **DRUG:** Leucovorin (LV)
- **DRUG:** Nab paclitaxel
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT06370754
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-30
- **Primary completion:** 2026-04-30
- **Final completion:** 2027-04-30
- **Target enrollment:** 117 (ESTIMATED)
- **Last updated:** 2024-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06370754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06370754, "Newly Emerging Immunotherapy for Pancreatic Cancer Treatment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06370754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*